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Abstract Type X collagen expression is restricted to hypertro-
phic chondrocytes in the endochondral growth plate. Transient
transfection of reporter constructs containing the human colla-
gen X promoter into primary growth plate chondrocytes identi-
¢ed a cis-acting positive regulatory DNA element(s) that has
cell-speci¢c enhancer properties and binds a nuclear protein ex-
pressed speci¢cally in growth plate chondrocytes. Functional
disruption of this region results in a signi¢cant reduction in
the activation of reporter gene transcription. The identi¢ed en-
hancer is a major element controlling both high-level and cell-
speci¢c expression of type X collagen gene.
# 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
During endochondral ossi¢cation, growth plate chondro-
cytes go through several stages of di¡erentiation, including
proliferation, maturation, and hypertrophy (e.g. see [1]).
Type X collagen expression is restricted almost exclusively
to hypertrophic chondrocytes [2], and the protein, a major
product of these cells, appears to assemble into a hexagonal
lattice similar to that formed by type VIII collagen [3].
Although the exact function of the collagen X gene remains
to be determined, mutations found predominantly in the car-
boxyl-terminal non-collagenous domain of protein cause the
human metaphyseal chondrodysplasia, type Schmid [4^6]. In
situ hybridization and nuclear run-o¡ studies have shown that
type X collagen expression by hypertrophic chondrocytes is
controlled at the transcriptional rather than translational level
[7,8]. The mechanisms responsible for the tightly regulated
expression of mammalian collagen X genes have been only
partially characterized, although the presence of both positive
[9^11] and negative [11,12] regulatory elements has been im-
plicated. Here we show for the ¢rst time that a novel cell-
speci¢c enhancer element is responsible for controlling the
highly regulated expression pattern of collagen X.
2. Materials and methods
2.1. Promoter constructs
Promoter fragments for use in expression constructs were generated
by either restriction enzyme digestion or PCR from the human lamb-
da genomic clone [HX3] [9]. pCAT Promoter and enhancer reporter
vectors as described were obtained from Promega. Transfection grade
DNA was prepared using a double cesium chloride banding method
[13] or the Qiagen column puri¢cation technique. The concentration
and purity of the plasmid preparations were determined spectrophoto-
metrically at 260/280 nm [13].
2.2. Cell culture
Growth media and supplements for cell culture were obtained from
Gibco BRL. Bacterial collagenase (type 1A) was obtained from Sigma
Chemicals. Bovine fetal calves (second trimester [14]) were obtained
from a local abattoir and the long bones used as a source of growth
plate and epiphyseal chondrocytes as described previously [9]. Chon-
drocytes were plated at 1U106 cells/cm2 in NUNC tissue culture
dishes (9 cm2) and maintained in DMEM bu¡ered to pH 7.2 with
10 mM HEPES and containing 0.37% (w/v) sodium bicarbonate, pen-
icillin (100 units/ml), streptomycin (100 mg/ml), 2 mM glutamine and
10% (v/v) fetal calf serum (FCS). The medium was replaced on alter-
nate days and all cultures were maintained at 37‡C in a 5%:95% (v/v)
CO2 :air atmosphere. RT-PCR was used to con¢rm the expression of
collagen X in growth plate but not in epiphyseal chondrocytes.
Normal human skin ¢broblasts and HeLa cells were maintained in
DMEM supplemented with penicillin (100 units/ml), streptomycin
(100 mg/ml), gentamicin (10 mg/ml), 2 mM glutamine, and 5% (v/v)
fetal calf serum. For transfection purposes ¢broblasts and HeLa cells
were plated into 9-cm2 dishes at a density of 2.5U105 cells/dish on the
day before transfection. The growth medium was replaced on the
following morning, at least 2 h before transfection.
2.3. Transfection and CAT assays
Transient transfections were performed by calcium phosphate co-
precipitation [9]. Growth plate and epiphyseal chondrocyte prepara-
tions were treated with bovine testes hyaluronidase (4 units/ml) (Sig-
ma) for 24 h prior to and for the ¢rst 4 h following transfection [15].
Each dish of cells was co-transfected with 20 Wg of the collagen X
promoter CAT vector and 3 Wg of a plasmid containing the human
growth hormone (hGH) gene driven by a CMV promoter (Hybrid-
tech). Four hours post-transfection, cells were shocked by the addition
of 20% (v/v) DMSO (Sigma) in PBS (without Mg2þ and Ca2þ) for
1 min. The cell layer was then washed twice with PBS (without Mg2þ
and Ca2þ) and the growth medium replaced. Forty-eight hours post-
transfection, the growth medium was aspirated and used for assay of
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hGH (Tandem-R hGH ImmunoRadioMetric assay kit, Hybridtech).
Cell layers were suspended in 150 Wl of 0.25 M Tris^HCl pH 8.0 and
extracts prepared by three rounds of freezing in dry ice^ethanol/thaw-
ing at 37‡C, followed by vigorous vortexing. Cell debris was removed
by microfuging (10 min), the cell extract heated to 68‡C for 10 min to
inactivate endogenous acetylases and stored at 370‡C.
CAT assays were performed on cell extracts (50 Wl) as described
previously [16]. Variations in transfection e⁄ciencies were standar-
dized using the data from the human growth hormone assay. All
values are given as meanSS.E.M. (n=6 unless otherwise stated).
2.4. Preparation of nuclear extracts
Nuclear extracts from collagen X-expressing hypertrophic chondro-
cytes were prepared [17] and mobility shift assays on 32P-labeled en-
hancer-derived fragments performed as previously described [18].
3. Results and discussion
3.1. Identi¢cation of an upstream positive regulatory element
We have previously shown that nucleotides 32411 to +34
of the type X collagen promoter directed strong CAT expres-
sion in the growth plate chondrocytes but weak or no expres-
sion in epiphyseal chondrocytes or ¢broblasts [9]. By examin-
ing a more detailed series of deletion constructs, a region
from 32411 to 31900 was found to be essential for the
high-level and cell-speci¢c expression (data not shown). A
major reduction in CAT activity (99%S5% to 4%S1%) was
noted when the sequences from 32411 to 31900 were deleted,
clearly indicative of the presence of a strong cell-speci¢c ele-
ment.
3.2. The upstream positive regulatory element behaves as an
enhancer
The potential enhancer activity of the 32411 to 31900
human COL10A1 promoter element was tested by inserting
the fragment into the pCAT promoter vector which contains
the SV40 promoter, but lacks an enhancer (Fig. 1). The pCAT
promoter vector alone gave no detectable activity in either
growth plate chondrocytes or ¢broblasts whereas the pCAT
control vector containing both the SV40 promoter and en-
hancer produced high-level expression in both cell types
(Fig. 1). The pCAT promoter vector containing the 32411
to 31900 fragment of the COL10A1 promoter supported
high-level CAT expression in growth plate chondrocytes in
both the positive (90%S5%) and the negative (70%S3%)
orientation. This e¡ect is cell-speci¢c since the same constructs
gave no expression in ¢broblasts (Fig. 1). A similar enhancing
e¡ect was observed when the 512-bp fragment was placed
upstream of a HSV TK promoter driving a CAT reporter
gene (data not shown). To more ¢nely map the location of
the enhancer, the 512-bp insert in the pCAT-Pro-512+ve plas-
mid was subdivided into two smaller fragments by restriction
digestion with SpeI: one of 151 bp (32411 to 32261) and the
3-prime 361 bp (32260 to 31900). However, neither the
pCATPro-151 nor the pCAT-Pro-361 plasmid induced CAT
expression in growth plate chondrocytes (Fig. 1). In addition,
similar patterns of CAT activity were observed upon trans-
fection of the promoter constructs either in the absence of the
hGH transfection control plasmid or when using liposome-
mediated transfection protocols (data not shown).
3.3. The enhancer element is recognized by a growth plate
speci¢c factor
One explanation for the loss of the enhancer activity
observed upon subdivision of the 512-bp fragment at the
SpeI site is that the cis regulatory element is located in the
vicinity of the SpeI site at base 32260 in the distal promoter.
We therefore generated a double-stranded oligomer contain-
ing sequences from 32273 to 32244 (5P-TAAAGCCACA-
GACTAGTCACTTCAAACAGC-3P [SpeI site underlined])
to determine by band shift analyses whether a nuclear protein
from growth plate chondrocytes bound this region. Growth
plate chondrocyte-derived nuclear extract with the 32P-labeled
30-bp enhancer-derived fragment gave a single speci¢c gel-
retarded band compared to labeled probe alone (Fig. 2B,
lane 2 vs. lane 1, respectively). This interaction was shown
to be speci¢c since a 500-fold excess of unlabeled fragment
completely abolished binding of the growth plate chondrocyte
Fig. 1. Localization and disruption of a cell-speci¢c enhancer element in the distal promoter of the COL10A1 gene. A: To examine the cell
speci¢city of the upstream cis-acting positive regulatory elements, short fragments of the distal promoter were prepared and cloned into the en-
hancerless CAT vector containing the SV40 heterologous promoter (pCAT promoter). Constructs were prepared as described in Section 2. The
small black box represents the SV40 promoter element, the larger black box the SV40 enhancer, and the hatched box the human distal pro-
moter region from between 32411 and 31900. B: Values (meanSS.E.M., n=6) were standardized for transfection e⁄ciency using the results
from the human growth hormone assay as described in Section 2. Data are expressed relative to the CAT activity in type X collagen-expressing
cells transfected with pCAT control (de¢ned as 100%).
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nuclear protein to the labeled 30-bp fragment (Fig. 2B, lane
4). Using the same 32P-labeled 30-bp enhancer-derived frag-
ment with HeLa cell-derived nuclear extract (-ve control), a
di¡erent retardation pro¢le consisting of two distinct mobili-
ty-shifted bands was observed (Fig. 2B, lane 6). To further
de¢ne the sequence recognized by the putative positive regu-
latory factor(s) contained within the growth plate chondrocyte
nuclear extract, additional competition experiments were per-
formed with sub-fragments of the 30-bp sequence. The bind-
ing of the growth plate chondrocyte-speci¢c protein to the
32P-labeled 30-bp enhancer fragment could be completely ab-
lated by introducing a 500-fold excess of unlabeled competitor
fragment which constituted the most 5P 22 bases of the 30-bp
enhancer domain (Up; 32273 to 32252: 5P-TAAAGCCA-
CAGACTAGTCACTT-3P ; Fig. 2B, lane 3). In contrast, the
most 3P 22 bases (Do) of the 30-bp enhancer failed to interfere
with protein binding and subsequent gel retardation (Fig. 2B,
lane 5). Taken together, these data show that the putative
positive trans-acting factor binds within a speci¢c 22-bp se-
quence located between 32273 and 32252 in the collagen X
gene promoter/enhancer region that includes the SpeI site at
32260. Examination of the entire sequence comprising the 30-
bp enhancer using a DNA sequence analysis package (http://
transfac.gbf.de/cgi-bin/patSearch/patsearch.pl/) failed to iden-
tify any known positive or negative regulating transcription
factor recognition motifs, suggesting that the cell-speci¢c fac-
tor binding this sequence is novel.
3.4. Sequences around 32260 direct high-level CAT activity in
chondrocytes
The 30-bp fragment (32273 to 32244) that binds a speci¢c
protein expressed in growth plate chondrocytes was tested to
see if it could drive cell-speci¢c transcription from a heterol-
ogous promoter. Neither a single copy of the fragment, nor
three concatenated copies placed upstream of the TK pro-
moter driving a CAT gene produced detectable transcription
in growth plate chondrocytes, although transfection was suc-
cessful based on hGH assays and the CAT activities produced
by the positive controls (data not shown). Thus the 30-bp
region of the promoter located between 32273 and 32244
appears necessary but not su⁄cient for the activation of the
collagen X gene in hypertrophic chondrocytes. However, the
importance of the 30-bp region’s contribution to promoter
activation was con¢rmed when the deletion of ¢ve nucleotides
of the SpeI site (pCAT-Pro-507-ve, bases 32262 to 32258) in
the 512-bp enhancer fragment reduced reporter gene activity
from the control (pCAT-Pro-512-ve, see Fig. 1) level of
100%S10% (n=3) to 42%S4% (n=6) in growth plate chon-
drocytes.
3.5. Interpretation of the collagen X promoter analysis
We present clear evidence that the sequences from 32411 to
31900 of the COL10A1 gene contain a strong enhancer ele-
ment capable of driving high-level CAT expression in a
growth plate chondrocyte speci¢c fashion (Fig. 1). The en-
hancer activity is completely lost if the 512-bp enhancer frag-
ment is cut into two (151 and 361 bp, respectively) at the
internal SpeI site, neither fragment being able to enhance
any cell-speci¢c transcription (Fig. 1). One explanation for
the complete loss of enhancer activity upon SpeI cleavage of
the active 512-bp fragment is that the enhancer element in-
cludes the SpeI site as part of the DNA binding site for the
transcription/enhancer complex. Indeed, the 30-bp sequence
£anking and including the SpeI site binds a transcription com-
plex present in the nuclei of growth plate chondrocytes but
not in HeLa cells (Fig. 2). If the identi¢ed transcription com-
plex is the sole factor responsible for generating the detected
enhancer activity, the 30-bp sequence containing the binding
site would be able to substitute completely for the 512-bp
enhancer element and drive expression speci¢cally in growth
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cold Spe-30mer 500x
cold Do 550
1     2      3     4     5     6
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-2411 -2260 -1900
-2273 -2252
-2273 -2244
-2265 -2244
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Hela B
GP A
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+     +      +     +     +     +
-      +      +     +     +      -
-      -       -      -      -      +
-      -       +     -      -       -
-      -       -      +     -       -
-      -       -      +     +      -
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B
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Fig. 2. A 30-bp fragment in the distal promoter is bound by a spe-
ci¢c trans-acting factor in growth plate chondrocytes. A: A sche-
matic diagram of the 512-bp human collagen X gene enhancer frag-
ment. Probes for band shift studies were localized around the
position of a SpeI restriction endonuclease site at 32260. B: Elec-
trophoresis mobility shift assay using a 32P-labeled double-stranded
DNA fragment representing nucleotides of 32273 to 32244 (Spe-
30mer Probe) of the human collagen X gene promoter and nuclear
precipitates (np) from either collagen X-expressing growth plate
(GP) chondrocytes or negative control HeLa cells. The electropho-
retic position of the free 32P-labeled probe is shown in lane 1 and
indicated by the arrow labeled ‘Free’. The presence of a single gel-
retarded band after incubation with growth plate nuclear precipi-
tates is indicated by the arrow marked GP A in lane 2. The interac-
tion of the Spe-30mer Probe with this protein can be completely
abolished by incubation with 500-fold excess of unlabeled Spe-
30mer Probe (lane 4) or an unlabeled double-stranded DNA frag-
ment constituting nucleotides 32273 to 32252 (Up, lane 3). The re-
tarded band observed from growth plate nuclear precipitates cannot
be competed for by a 500-fold excess of an unlabeled DNA segment
constituting nucleotides 32266 to 32244 (Do, lane 5). In cells that
do not express the collagen X gene, the 30-bp fragment produces
two distinct mobility-shifted bands (lane 6) labeled HeLa and HeLa
B, respectively.
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plate chondrocytes. However, we demonstrated that neither a
single nor multiple copies of the 30-bp fragment is capable of
producing enhancer activity, suggesting that this element must
be acting in concert with another located elsewhere in the 512-
bp fragment. Since it is clear that neither sequences 5P nor 3P
of the SpeI site can generate enhancer activity in isolation, we
ablated the SpeI sequence within the 512-bp enhancer frag-
ment, anticipating that this would abolish enhancer activity.
However, activity of the resulting construct was not abolished
but, instead, signi¢cantly decreased (pCAT-pro-507-ve, Fig. 1).
Therefore, further elements located both upstream and down-
stream of the SpeI site must be present and cooperate to
produce the full strength enhancer activity exhibited by the
512-bp fragment. Interestingly, none of these sites is capable
of producing enhancer activity in isolation. These data are the
¢rst to demonstrate the presence of a complex enhancer ele-
ment that appears both necessary and su⁄cient for high-level
and cell-speci¢c expression of the human collagen X gene.
Whilst the enhancer element contained within the 512-bp frag-
ment is su⁄cient to produce both high-level and cell-speci¢c
expression of the collagen X gene, other factors located nearer
the transcription start site clearly modulate or ¢ne tune the
gene’s expression. For instance, sequences between positions
3452 and +1 control responsiveness to c-Raf [12], osteogenic
protein-1 (OP-1) or BMP7 [19]. In addition, recent data has
shown that the 31870 to 32407 region of the human collagen
X promoter is involved in the negative regulation of transcrip-
tion in response to parathyroid hormone (PTH) and parathy-
roid hormone related peptide (PTHrP) [20]. Thus, it may be
that the negative regulatory PTH/PTHrP response element
interacts either competitively or cooperatively with the trans-
acting factors that bind to the enhancer element described
here to regulate transcription. To date, the transcription fac-
tors regulating the enhancer activity of the human collagen X
gene have not been identi¢ed. Further analyses of the 32411
to 31900 region of the promoter will enable the identi¢ca-
tion of the other sequences required for the full enhancer
activity and the characterization of the trans-acting factors
involved.
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